Leukocyte Transfer Factor Purification via Segmented Filtration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing transfer factors lack high-purity extraction, often resulting in products contaminated with other components that interfere with their metabolic action, and are either costly or difficult to implement due to requirements for large amounts of antigen or cumbersome handling processes.
Innovation Solution
A process involving five freeze-thaw cycles of leukocyte concentrate, followed by dialysis with a 12 kDa cutoff, serial tangential ultrafiltration with 10 kDa and 1 kDa cutoffs, and subsequent Size exclusion Ultra Performance Liquid Chromatography (SE-UPLC) for identification and quantification, which results in a high-purity transfer factor with anti-proliferative activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional purification methods (Sephadex chromatography, single filtration) are used, then the process is simple to operate, but the purity of transfer factor is insufficient due to multiple interfering components
Solution Approach 1:
The purification process is divided into multiple sequential stages: initial filtration to remove debris, dialysis to separate by molecular size, and Sephadex chromatography for final purification. Each stage targets specific contaminants, progressively improving purity without requiring overly complex equipment at any single step.
Solution Approach 2:
Buffer solutions serve as intermediaries throughout the purification process. Buffers control pH and ionic strength during dialysis and chromatography, enabling selective separation of transfer factor from interfering components while maintaining protein stability. The buffer system acts as a mediator that facilitates purification without direct contact between problematic components.
2Manufacturing precision
If antigen-based purification is used, then high purity transfer factor is obtained, but the cost increases significantly due to large amounts of antigen required
Solution Approach 1:
The method extracts transfer factor from leukocyte supernatant through physical and chemical properties (molecular size, charge, solubility) rather than requiring antigen-antibody interactions. Dialysis removes larger proteins, while Sephadex chromatography separates transfer factor based on its unique molecular characteristics, eliminating the need for expensive antigen materials.
Solution Approach 2:
The purification relies on changing physical parameters (pH, ionic strength, molecular size separation) rather than requiring specific biological interactions. By adjusting buffer conditions and using size-exclusion chromatography, transfer factor is purified based on its inherent physical properties, avoiding the need for large amounts of antigen.
3Productivity
If egg-based sources are used, then transfer factor can be obtained, but handling difficulties and contamination with lipid fraction occur
Solution Approach 1:
The method extracts transfer factor directly from leukocyte supernatant obtained through centrifugation, bypassing the need for egg handling entirely. This approach eliminates the technical difficulties of yolk-white separation and lipid contamination while maintaining high productivity through efficient cellular source utilization.
4Ease of manufacture
If highly raw factor is obtained, then the production process is simple, but the factor action is masked by large number of components
Solution Approach 1:
The production process is segmented into two distinct phases: a simple initial phase obtaining raw factor through centrifugation and dialysis, followed by a purification phase using Sephadex chromatography. This segmentation allows the process to maintain simplicity where possible while introducing purification only where necessary to remove interfering components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively produces a high-purity transfer factor with anti-proliferative activity, avoiding contamination issues and reducing costs by eliminating the need for antigen-based purification, while simplifying the handling of egg-based sources and improving the availability of the final product.
Implementation Method 1
subjecting a leukocyte concentrate to five freeze-thaw cycles, wherein, in each cycle, the concentrate is frozen at - 20°C for one week, and then completely thawed
Implementation Method 2
subjecting the freeze-thaw product of step (a) to dialysis using a dialysis membrane with a 12 kDa cutoff
Implementation Method 3
subjecting the dialyzed product of step (b) to serial tangential ultrafiltration, first with a 10 kDa cutoff and then with a 1kDa cutoff
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a method for producing a transfer factor. The method comprises the following steps: freezing and thawing of peripheral-blood leukocytes, dialysis, tangential ultrafiltration, identification and quantification using high-resolution, molecular-exclusion liquid chromatography, and in vitro biological validation. The resulting product is suitable for medical use.